Strides Pharma Science Ltd
STARStrides Pharma Science Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
The sharpest disagreement: profits are rising, but only 42% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (164 weeks in) while the P/E sits at the 52nd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +50.0% year on year, and 42% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Strides Pharma Science Ltd trades at ₹1,075, in a confirmed uptrend and 164 weeks into that stage. That is +10.9% against its own 200-day average. It sits at 77% of a 52-week range of ₹796 to ₹1,157. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 164 of stage 2, confirmed. At ₹1,075 it trades +10.9% versus its 200-day average and sits at 77% of its 52-week range (₹796–₹1,157).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +115% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 52nd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Strides Pharma Science Ltd trades at 16.6× P/E, mid-range by its own standards (52nd percentile). Its long-run median P/E is 16.0×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 16.6× is mid-range by its own standards (52nd percentile), against a long-run median of 16.0× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −84.5% against a +21.9% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +23.8%/yr price move, ~+19.5%/yr came from earnings growth and ~+4.3 pp from the multiple (expanding); over 10y, of the +7.2%/yr price move, ~+12.8%/yr came from earnings growth and ~−5.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Strides Pharma Science Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +6.4% | +9.6% | +7.9% | +5.4% |
| Profit | −84.0% | — | +17.4% | +19.7% |
| EPS | −84.5% | — | +15.1% | +17.4% |
| Share price | +21.9% | +73.9% | +23.8% | +7.2% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
41.2/100 — rank 31 of 43 in Pharma - Formulators · 76% evidence confidence
Strides Pharma Science Ltd scores 41.2 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 31. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 9.5 + 13.4 + 11.3 + 7 = 41.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Strides Pharma Science Ltd reported ₹1,323 Cr of revenue in the Mar 26 quarter, +11.2% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 5.4% a year. The last full year, FY26, came in at ₹4,859 Cr. The last four reported quarters add to ₹4,859 Cr.
Strides Pharma Science Ltd reported ₹1,323 Cr of revenue in the Mar 26 quarter, +11.2% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 5.4% a year. The last full year, FY26, came in at ₹4,859 Cr. The last four reported quarters add to ₹4,859 Cr.
FY26 revenue came in at ₹4,859 Cr (+6.4% on the year), capping 10 years at 5.4% compound. The latest quarter (Mar 26) printed ₹1,323 Cr, +11.2% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +6.4% growth against the decade's 5.4% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.4% over the last 4 quarters against +10.5%/yr over the last 8 — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 18.0% this quarter (+0.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Strides Pharma Science Ltd's operating margin is 18.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged −17.0% to 19.0%. The current quarter sits inside that band.
Strides Pharma Science Ltd's operating margin is 18.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged −17.0% to 19.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 18.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −17.0%–19.0%, and FY26's 19.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.2 pp year on year while gross margin went +1.4 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +50.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Strides Pharma Science Ltd earned ₹129 Cr of net profit in the Mar 26 quarter, +50.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹575 Cr. The 10-year compound rate is 19.7%. That is 9.8% of the quarter's revenue. The same quarter a year earlier earned ₹86.0 Cr.
Strides Pharma Science Ltd earned ₹129 Cr of net profit in the Mar 26 quarter, +50.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹575 Cr. The 10-year compound rate is 19.7%. That is 9.8% of the quarter's revenue. The same quarter a year earlier earned ₹86.0 Cr.
Mar 26 profit was ₹129 Cr, +50.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹575 Cr (−84.0%), and the 10-year compound rate is 19.7%.
Why profit moved: revenue contributed +11.2% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +41.9% vs revenue +6.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 42% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 42% of Strides Pharma Science Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹703 Cr of operating cash against ₹575 Cr of profit. After ₹644 Cr of capital spending, ₹59.0 Cr was left as free cash.
FY26: operating cash of ₹703 Cr against reported profit of ₹575 Cr, leaving free cash of ₹59.0 Cr after ₹644 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 42% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 42%: the cash cycle stretched 29 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 29 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 157-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Strides Pharma Science Ltd's cash conversion cycle runs 157 days in FY26, up from 128 days in FY21. Capital spending ran ₹694 Cr over the last 3 years. At FY26 sales of ₹4,859 Cr each day of that cycle holds about ₹13.3 Cr, so roughly ₹2,090 Cr sits inside the business at any moment.
FY26: debtors at 97 days, inventory at 305 days — roughly 10.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 157 days, looser than FY21's 128.
The full loop: cash goes out to suppliers and production on day 0; stock waits 305 days to sell; customers pay about 97 days after that; and suppliers themselves are paid at 244 days — netting out to the 157-day cycle.
In money terms: at FY26 sales of ₹4,859 Cr, each day of the cycle holds about ₹13.3 Cr — so the 157-day loop keeps roughly ₹2,090 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹694 Cr over the last 3 fiscal years against ₹608 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹447 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 18% and the ROIC − WACC spread is +0.2 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Strides Pharma Science Ltd earns a ROCE of 18% in FY26. That is up from a trough of −5% in FY22. Return on invested capital clears the cost of that capital by +0.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.8% net margin on 0.71× asset turns.
FY26 ROCE is 18%, recovered from a FY22 trough of −5% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 11.8% net margin × 0.71× asset turns × 2.19× balance-sheet leverage ≈ 18.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.2% − 12.0% = a +0.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.57.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Strides Pharma Science Ltd carries total debt of ₹1,758 Cr against shareholder equity of ₹3,149 Cr as of Mar 26, a debt-to-equity of 0.56. On the annual view that ratio went from 1.27 in FY22 to 0.56 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹1,758 Cr against shareholder equity of ₹3,149 Cr — a debt-to-equity of 0.56. On the annual view, debt-to-equity went from 1.27 (FY22) to 0.56 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 2.8 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 2.8 points of Strides Pharma Science Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 15.4% of the company. Promoters moved +2.1 points over the same window, to 27.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −2.8 points over 8 quarters to 15.4%; Promoters: +2.1 points over 8 quarters to 27.9%; Foreign institutions: +1.7 points over 8 quarters to 28.4%.
Why the register moved: rotation — foreign institutions +1.7 points against domestic institutions −2.8 points over 8 quarters, with promoters +2.1 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Strides Pharma Science Ltd: the Z-score reads 2.65. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.65 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.65.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Strides Pharma Science Ltd this page | 16.6× | ₹9,402 Cr | No read | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Strides Pharma Science Ltd's share price today?
Strides Pharma Science Ltd trades at ₹1,075, +21.9% over the past year. The company is valued at ₹9,402 Cr. The stock sits at 77% of its 52-week range of ₹796–₹1,157, +10.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 164 weeks in. — as of 24 July 2026.
What were Strides Pharma Science Ltd's latest quarterly results?
Strides Pharma Science Ltd reported revenue of ₹1,323 Cr and net profit of ₹129 Cr for the Mar 26 quarter. Revenue rose 11.2% and profit rose 50.0% year on year. Earnings per share were ₹13.77. The operating margin was 18.0%, 0.0 pp higher than a year earlier. — as of 24 July 2026.
What is Strides Pharma Science Ltd's revenue?
Strides Pharma Science Ltd reported revenue of ₹1,323 Cr in the Mar 26 quarter, +11.2% year on year. For the full FY26 fiscal year, revenue was ₹4,859 Cr (+6.4%). Over the last 10 years revenue compounded at 5.4% a year. — as of 24 July 2026.
What is Strides Pharma Science Ltd's profit?
Strides Pharma Science Ltd earned ₹129 Cr of net profit in the Mar 26 quarter, +50.0% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹575 Cr. The operating margin ran 18.0% in the latest quarter. — as of 24 July 2026.
What is Strides Pharma Science Ltd's market cap?
Strides Pharma Science Ltd's market capitalisation is ₹9,402 Cr at a share price of ₹1,075. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Strides Pharma Science Ltd's P/E ratio?
Strides Pharma Science Ltd trades at a P/E of 16.6×, at the 52nd percentile of its own 10-year range, against a long-run median of 16.0×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Strides Pharma Science Ltd pay a dividend?
Yes — Strides Pharma Science Ltd's dividend payout was 8% of profit in FY26, and it recorded a payout in 10 of its last 13 reported fiscal years. 2 of those years show a negative ratio because profit itself was negative. — as of 24 July 2026.
Is Strides Pharma Science Ltd overvalued?
On its own history, Strides Pharma Science Ltd looks mid-range against its own history: its P/E of 16.6× sits at the 52nd percentile of its 10-year range (long-run median 16.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Strides Pharma Science Ltd growing?
Yes — Strides Pharma Science Ltd is growing: latest-quarter revenue +11.2% year on year, profit +50.0%, and the margin +0.0 pp at 18.0%. The 10-year compound rates are 5.4% (revenue) and 19.7% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Strides Pharma Science Ltd performing?
Strides Pharma Science Ltd is in a confirmed uptrend, 164 weeks in. Its latest quarter's revenue rose 11.2% and profit rose 50.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Strides Pharma Science Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 164 of stage 2), trading +10.9% versus its 200-day average and at 77% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Strides Pharma Science Ltd beating the market?
Not lately — on a trailing-13-week view Strides Pharma Science Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +115% against the NIFTY 500's +274% — behind the index over the full window. — as of 24 July 2026.
Will Strides Pharma Science Ltd's share price go up?
This page publishes no price forecast for Strides Pharma Science Ltd. What it measures instead: the share price is ₹1,075, the price is in a confirmed uptrend 164 weeks in. Its P/E of 16.6× sits at the 52nd percentile of its own 10-year range. — as of 24 July 2026.
Who owns Strides Pharma Science Ltd?
Promoters hold 27.9% of Strides Pharma Science Ltd, foreign institutions 28.4%, domestic institutions 15.4% and the public 28.3% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 2.8 points over 8 quarters. — as of 24 July 2026.
Does Strides Pharma Science Ltd have too much debt?
It is moderate — Strides Pharma Science Ltd's debt-to-equity is 0.57, and operating profit covers the interest bill 5×. FY26 borrowings were ₹1,758 Cr against equity of ₹3,107 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Strides Pharma Science Ltd's capex?
Strides Pharma Science Ltd spent ₹694 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹644 Cr, with ₹447 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Strides Pharma Science Ltd's cash flow?
Strides Pharma Science Ltd generated ₹703 Cr of operating cash flow in FY26 and ₹59.0 Cr of free cash flow after ₹644 Cr of capital spending. Reported profit that year was ₹575 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Strides Pharma Science Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 42% of Strides Pharma Science Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹703 Cr against reported profit of ₹575 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Strides Pharma Science Ltd?
On the balance sheet, the Z-score reads 2.65 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 24 July 2026.
Where is Strides Pharma Science Ltd in its business cycle?
Strides Pharma Science Ltd's FY26 operating margin was 19.0%, against a 13-year band of −17.0%–19.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 18.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Strides Pharma Science Ltd story?
The sharpest disagreement: profits are rising, but only 42% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Strides Pharma Science Ltd a stock worth studying right now?
This is not investment advice. The machine read: Strides Pharma Science Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.